logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

Preclinical evaluation of the antibody fragment targeting fibronectin EDB in the theranostics of radioactive iodine-resistant thyroid cancer

delete2026-05-10
delete0
PRE
AI
W
Wenyi Luo
X
Xiaoli Zhang
Q
Qian Liu
Y
Yuhong Shi *
X
Xue Jiang *
DOI：10.1016/j.bioorg.2026.109980delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• The EDB antibody was an engineered anti-EDB-FN antibody fragment, for theranostic management of radioactive‑iodine-resistant thyroid cancer (RAIR-TC). • 89Zr-DFO-EDB provided high-contrast PET imaging independent of NIS expression, with tumor uptake peaking at 13.8%ID/g. • Single 100 μCi dose of 177Lu-DTPA-EDB induced 78.5% tumor regression and 65% necrosis in CAL-62 xenografts with only transient 5% weight loss. • Favorable labeling efficiency (>90%), radiochemical purity (>99%), and stability (>98%) for both diagnostic and therapeutic radioconjugates support rapid clinical translation.
Keywords:
EDB-FN
theranostics
radioactive iodine-resistant thyroid cancer
antibody fragment
PET imaging

Journal

Bioorganic Chemistry cover
Bioorganic Chemistry
IF:
4.7
Papers:
2.2K
Citations:
2.5W

Organization

No organization information available